Home › Research › Topics › rivastigmine
rivastigmine
271 studies tagged rivastigmine, dated 1981-01-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
271 studies carry this tag.
Date range
1981 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 15
- Neurology 11
- Journal of the American Geriatrics Society 9
- Research Square 8
- medRxiv 8
138 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
The Integrated Alzheimer's Disease (AD) Rating Scale (iADRS) is a composite tool that combines scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL).
-
ABSTRACTBackground:This systematic overview reports findings from systematic reviews of randomized controlled trials of pharmacological and non-pharmacological interventions for behavioural and psychological symptoms of dementia (BPSD).
-
The evidence to support a specific time frame for discontinuation of Alzheimer's disease treatment is limited.
-
Vascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer's disease (AD).
-
Thirty-three randomized controlled trials were identified evaluating 15,971 participants (9,103 (57%) female).
-
39/100
The objective of the review is to assess the effect of metformin on the risk, progression and severity of Alzheimer's disease and other forms of dementia, as well as any measures of cognitive performance or impairment.
-
The prevalence of Alzheimer's disease (AD) continues to rise, while treatment options for cognitive impairment are limited.
-
52/100
Overall, 304 patients receiving cholinesterase inhibitors/memantine also received anticholinergics.
-
A large number of non-pharmacological interventions for BPSD were identified.
-
After taking into consideration a possible protopathic bias in the 2 years preceding the AD diagnosis date, benzodiazepine use was not associated with an increased risk of developing AD.
-
Patients on galantamine had longer mean persistence and better adherence compared with patients on donepezil, with a hazard ratio for discontinuation of 0.91 [95% confidence interval (CI) 0.87-0.96] and a relative risk for good adherence of 1.01 (95% CI 1.002-1.03).
-
Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes.
-
In APOE4/4 homozygotes receiving 150mg BID tramiprosate, efficacy in the traditional Mild AD patients (MMSE 20-26) was higher than the overall group (MMSE 16-26) and efficacy in the Mild patients (MMSE 22-26) was highest.
-
The major pharmacokinetic interactions identified concerned fluoxetine, paroxetine and ketoconazole when used with galantamine or donepezil.
-
68/100
Currently available data indicate superior therapeutic effects of combination treatment for Alzheimer dementia with memantine and acetylcholine esterase inhibitors in certain clinical contexts.
-
The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.
-
No differences between treated groups and placebo in adverse events or in study completion.
-
Key Messages: Our results suggest that benzodiazepine use is significantly associated with dementia risk.
-
Agitation is common and distressing in patients with Alzheimer-type dementia, but safe, effective treatments remain elusive.
-
Alzheimer's disease (AD) is the most common cause of dementia in the elderly.
-
The COMCID trial will identify the therapeutic potential of cilostazol.
-
50/100
The restricted use of BDZRs may contribute to dementia prevention in the elderly.
-
54/100
Patients who started ChEI therapy after the introduction of the coverage policy had a significantly longer persistence.
-
Author(s): Reus, Victor I; Fochtmann, Laura J; Eyler, A Evan; Hilty, Donald M; Horvitz-Lennon, Marcela; Jibson, Michael D; Lopez, Oscar L; Mahoney, Jane; Pasic, Jagoda; Tan, Zaldy S; Wills, Cheryl D; Rhoads, Richard; Yager, Joel
-
Twelve studies were included in the final analysis.
-
Four-week changes in NPI-Q total scores did not differ significantly between the treatment and placebo groups.
-
A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric™) is available in the USA for patients with moderate to severe Alzheimer's disease (AD) on stable memantine and donepezil therapy.
-
38/100
Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP).
-
21% (7065) of the cohort had a record of mental illness at study entry, 25% (8300) had a record of challenging behaviour, and 49% (16,242) had a record of prescription of psychotropic drugs.
-
Utilization patterns of psychotropic drugs in institutionalized patients with dementia have changed over the past decade.
-
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions.
-
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl D-aspartate receptor antagonist memantine.
-
The mean age of 35,570 new users of cholinesterase inhibitors (30,174 users of donepezil, 1,176 users of galantamine, 4,220 users of rivastigmine) was 82; 75% were women, and 82% were white.
-
Memantine monotherapy improved cognition, behavior, activities of daily living, global function, and stage of dementia and was well-tolerated by AD patients.
-
PRE2DUP method gives highly accurate drug use periods for most drug classes, especially those meant for long-term use.
-
The purpose of the study was to evaluate the influences of cholinesterase inhibitors on sleep pattern and sleep disturbance.
-
The predefined superiority of donepezil to the placebo was not confirmed in either active group in the primary analysis.
-
In total, 100 subjects completed the study.
-
Food and Drug Administration–approved information and public advertisements belie neurodegenerative risks for second-generation antipsychotics in affective illness.
-
Major categories of reasons for use of antipsychotic medications in the 204 NH residents in the study sample were behavioral (n = 171), psychiatric (n = 159), emotional states (n = 105), and cognitive diagnoses or symptoms (n = 114).
-
Ranolazine and metformin may be frequently co‐administered in subjects with chronic angina and co‐morbid type 2 diabetes mellitus (T2DM).
-
52/100
Two‐hundred and sixteen only subjects were randomized across 28 French expert clinical sites.
-
Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial.
-
Older adults with dementia commonly have multiple chronic conditions that prompt clinicians to prescribe medications.
-
Read the article, “Behavioral and Psychological Symptoms of Dementia: How Long Does Every Behavior Last, and Are Particular Behaviors Associated With PRN Antipsychotic Agent Use?” found on pages 22–37, carefully noting any tables and other illustrative materials that are included to enhance your knowledge and understanding of the content.
-
The addition of memantine resulted in stabilization of the Mini-Mental State Examination scores and Hasegawa dementia rating for 6 months, and then significantly declined at 12 months in both subgroups.
-
61/100
Thirty-three patients were included: the revaluation of anti-dementia treatment led to 22 discontinuations and 11 continuations.
-
This paper provides a comprehensive review of studies examining adherence and (or) persistence with dementia pharmacotherapy during the past decade, including a summary of the key patient-, drug-, system-, and provider-level factors associated with these measures.
-
Consumption increased by 49.72% between 2006 and 2011.
-
Between Dec 8, 2009, and Dec 23, 2011, we randomly allocated 278 patients to treatment: 133 to placebo and 145 to idalopirdine. 132 patients in the placebo group and 140 in the experimental group were included in the final analysis.
From across this tag
8 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
- Antihypertensive medication use and incident Alzheimer disease: the Cache County Study
- Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
- The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
- Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine1
- Comparison of cholinesterase inhibitor safety in real-world practice
- Individual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study
- Atypical antipsychotics for the treatment of dementia-related behaviors: an update